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1. INTRODUCTION 
 
1.1. Embryology of the liver 
The liver of vertebrates originates from an outgowth of the primitive gut wall caudal to the stomach, 
pancreas and gall bladder, and consists of endodermal and mesodermal components. These give rise 
to hepatoblasts and both sinusoidal-lining cells and connective tissue, respectively (Shiojiri et al. 
1991). The primitive hepatoblasts which surround the portal mesenchyme form a double layered 
cylinder of hepatocytes, the ‘ductal plate’, which remodels and migrates into the mesenchyme to 
form the intrahepatic bile ducts (Shiojiri et al. 1991) (Van Eyken et al. 1988). The hepatoblasts 
express the hepatocyte-specific protein alpha-fetoprotein (AFP) and albumin as they migrate into 
the portal stroma and additionally begin to express the bile duct specific marker, gamma glutamyl 
transferase (γ-GT) (Shiojiri et al. 1991). Initially intermediate filament expression is restricted to 
cytokeratin (CK) 8, but, during the later stages of ductular morphogenesis, the new ductal cells 
begin to express the characteristic biliary cytokeratins 7, 8, 18, and 19 (Moll et al. 1982), although 
continuing to express hepatocyte traits for the first 7-14 days (in rat) after birth (Shiojiri et al. 1991). 
In contrast, hepatoblasts without contact to the portal mesenchyme differentiate into hepatocytes, 
which form the liver cell plates and continue to express GGT until birth; the hepatocyte cytokeratin 
complement is restricted to 8 and 18. 
In the human developing liver, the first antigens detected in immature progenitor cells of the liver 
primordium are CK 8, CK 18, CK 19 and hepatocyte paraffin 1 (HepPar1) antigen at 4 weeks of 
gestation. Between 8 and 14 weeks‘ gestation, bipotential progenitor cells appear. They also express 
CK 14 but are negative for vimentin. Although AFP expression can first be detected at 4 weeks of 
gestation, at 9-10 weeks of gestation up to 50% of individual hepatoblasts are positive and the 
number of expressing cells continue to rise. At about this stage, hepatoblasts also express albumin 
and alpha1-antitrypsin. Between 14 and 16 weeks of gestation, as hepatoblasts differentiate into 
hepatocytes, CK 14 and CK 19 disappear, whereas hepatocytic markers (HepPar1, albumin, AFP) 
become more strongly expressed. In contrast, commitment to bile duct cells lineage is marked by 
increased expression of CK 19 (along with CKs 8 and 18), loss of CK14 and HepPar1 antigen and 
transient (from 9 –36 weeks) expression of vimentin. Starting from 20 weeks of gestation, bile ducts 
also show increasing immunoreactivity for CK 7. During the first weeks of biliary development 
from ductal plate cells (in about 7-9 weeks of gestation), the cells are also positive for AFP, which 
eventually becomes lost in developing bile duct cells (Haruna et al. 1996). 
The liver stem cell is defined as a progenitor cell without distinguishing structure or phenotypic 
markers that has the capacity to proliferate and produce progeny that may differentiate into either 
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biliary or hepatic cells (Sell 1990) (Thorgeirsson 1993; Thorgeirsson 1996). Thus, it appears that in 
the developing livers, hepatoblasts and primitive biliary cells belong to liver stem cells.  
 
1.2. Cell types of the postnatal liver 
The postnatal liver is composed of parenchymal cells (hepatocytes) and nonparenchymal cells 
(NPCs). Nonparenchymal cells in the liver include biliary epithelial cells (BECs), kupffer’s cells, 
pit cells, endothelial cells, hepatic stellate cells (HSC, synonyms are Ito cells or fat-storing cells) 
(Marceau et al. 1989). Hepatocytes comprise about 80% of total cellular population in human liver 
(60% in rat liver) and about 80% of hepatic tissue volume (in both humans and rats). BECs of all 
bile duct segments in the liver constitute only about 3-5% of total liver nuclear population and less 
than 1% of total liver mass. Hepatocytes and BECs belong to the epithelial cell. 
For a long time, it has been discussed whether there are liver stem cells in the postnatal liver. There 
are two arguments that do not support the existence of liver stem cells in the postnatal liver. First, 
the physiological liver cell renewal is very slow. It was concluded that only one of 20,000 to 40,000 
liver cells is dividing at any given time and the liver replaced itself in approximately 1 to 2 years. 
Up to now, there have been no strong evidence that liver stem cells are involved in liver cell 
renewal. Second, liver cells are not end-staged differentiated cells. Although hepatocytes are 
usually in proliferatively quiescent state, they are capable of entering the cell growth cycle once 
there is loss of liver parenchyma. The typical example is that liver regeneration after a 70% liver 
resection in rats is followed by proliferation of mature liver cells. Thus it seems unnecessary for 
liver stem cells to exist in mature liver. 
However, more and more studies have suggested that cells of stem cell potential exist in the liver, 
and these cells may be recruited to replace damaged liver cells when the injurious process to the 
liver is extensive or the injurious agent also inhibits proliferation of hepatocytes.  
In 1937, Kinosita first reported discovery of small round cells in livers of rats exposed to the 
carcinogen „butter yellow“, and in 1956 Farber coined the term „oval cells“ for this kind of small 
cells. A popular model (AAF/PH) to generate oval cells is to feed animals with 2-
acetylaminofluorence (AAF, which inhibits the proliferation of hepatocytes) before and after a two-
thirds partial hepatectomy. Oval cells are classically characterized by ovoid nuclei and scanty 
basophilic cytoplasm. They arise in the periportal area and can be seen proliferating and migrating 
from the portal tract areas into liver parenchyma. Oval cells share similar phenotypes with BECs 
(CK 7, CK 19, CK 8, CK 18), however, they also contain markers normally seen in fetal liver cells, 
such as albumin, AFP, CK14, stem cell factor and its receptor (c-kit). OV-1 and OV-6 are two 
monoclonal antibodies that recognize oval cells. Oval cells have been shown to differentiate into 
hepatocytes or biliary cells both in vivo and in vitro (Golding et al. 1995) (Dabeva and Shafritz 
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1993; Germain et al. 1988; Lazaro et al. 1998). Thus, oval cells are suggested to derive from a 
putative stem cell population in rodent liver when the replicative capacity of the hepatocytes is 
greatly impaired. 
In human diseased liver, oval-like cells were also discovered. Examination of the cell types 
involved in human ductular reactions has revealed small oval-like cells (small cells, ductular 
hepatocytes, small epithelial cells) in periportal zones. Ductular reaction is referred to the increase 
in ductular structures in the vicinity of portal tracts, accompanied by inflammatory cells and 
periductular fibrosis. Ductular reaction is a feature of many forms of human liver diseases, 
including regeneration, chronic cholestasis and cancer.  
In 1992, De Vos described the presence of „small cells“ in the periportal area in human liver 
specimen with chronic ductular reaction (De Vos and Desmet 1992). These cells had an oval shape 
with an oval or oblong nucleus. Under electron microscope, they could be divided into three types. 
Type I cells represented the most immature progenitor cells, type II cells (intermediate bile duct-
like cells) showed features of bile-duct cell differentiation, and type III cells (intermediate 
hepatocyte-like cells) displayed characteristics indicating hepatocellular differentiation. In 1996 
(Roskams et al. 1996) and 1998 (Roskams et al. 1998), Roskams again described similar 
heterogeneous small cells in focal nodular hyperplasia (FNH) and regenerating human liver after 
submassive necrosis. These cells are immunoreactive for chromogranin-A (immature progenitor 
cells and intermediate hepatocyte-like cells), CK 7 and CK 19 (immature progenitor cells and 
intermediate bile duct-like cells) and OV-6 (all small cells). 
Demetris (Demetris et al. 1996) and Haque (Haque et al. 1996) independently identified and 
characterized ductular hepatocytes (DHs) after submassive hepatic necrosis in human. They had a 
nuclear/cytoplasmic ratio that was higher than BECs or mature hepatocytes, and were located at the 
interface between the periportal connective tissue and liver cell plates. Immunohistochemical 
analysis of the highly proliferative DHs compartment shows it to be a heterogeneous population 
with unique phenotypic features. Although a subpopulation of DHs share phenotypic features with 
mature bile duct epithelium (CK19 positive) or hepatocytes (HepPar 1, albumin and alpha1 anti-
trypsin positive), they are also clearly different from both populations. Moreover, occasional DHs 
also co-expressed HepPar1 and CK19, indicative of both hepatocyte and ductular differentiation.  
Ruck described a population of small epithelial cells (SECs) that exhibit morphological and 
immunophenotypic features of the rodent oval cells in human hepatoblastoma (Ruck et al. 1996) 
and extrahepatic biliary atresia (Xiao et al. 1999). SECs co-express CK 7 (a marker of biliary 
differentiation) and albumin (a marker of hepatocytic differentiation), and also express oval cell 
associated antigens OV-1 and OV-6. SECs have also been demonstrated in various other liver 
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diseases, including alcoholic cirrhosis, chronic hepatitis and hepatocellular carcinoma, but not in the 
normal liver (Crosby et al. 1998a; Crosby et al. 1998b; Hsia et al. 1992). 
In summary, oval-like cells in human liver were discovered mostly in conditions under severe 
hepatic injury, or chronic and persistent hepatic injury, or hepatic carcinogenesis. Thus, it can be 
speculated that, as in the rodent liver, activation of the putative stem cell pool in the human liver 
takes place only if the replicative capacity of the hepatocytes is greatly impaired by endogenous or 
exogenous noxious stimuli. 
 
1.3. Putative location of liver stem cells in the liver 
Most investigators have generally accepted the hypothesis that there are cells in the liver with stem 
cell potential (Crosby and Strain 2001). However, the exact location of liver stem cells in the liver 
is unclear. As oval cells share similar phenotypes with BECs and organize in ductular structure, the 
biliary tree has always been hypothesized to contain liver stem cells (Golding et al. 1996) (Alison 
and Sarraf 1998; Alison et al. 1996b; Sigal et al. 1992). It has been demonstrated that liver damage 
in the rat induces hepatic stem cells from biliary epithelial cells (Alison et al., 1996a). With the 
cholangiogram method, the continuity between duct-like structures formed by oval cells and pre-
existing biliary tree had also been demonstrated (Dunsford et al. 1985) (Lenzi et al. 1992). Another 
convincing evidence is the inhibition of oval cell activation when bile ducts were damaged by 4,4‘-
diaminodiphenylmethane (DAPM) (Petersen et al., 1997). The anatomic region that connects bile 
canaliculi (formed by hepatocyte) and bile ductule (the smallest branch of bile duct, containing 
biliary cells) is named canaliculo-ductular junction (CDJ), or canals (openings or orifices) of 
Hering. This junction is believed to be the location of the putative liver stem cell (Sell 1990) 
(Lemire and Fausto 1991). However, cells located within or in contact with the portal stroma 
(Yavorkovsky et al. 1995), small non-descriptive cells around cholangioles, the periductular cells 
(Sell 1993), and small interlobular ducts all have been proposed as candidates for the site of the 
stem cells (Nomoto et al. 1992). 
 
1.4. The history of isolation and culture of hepatocytes and intrahepatic BECs 
In 1967, Howard and Pesch (Howard et al. 1967) first used collagenase to disaggregate adult rat 
liver tissue, with the resultant of successful isolation of viable and functional hepatocytes. Seglen 
(Seglen 1976) refined this technique by perfusing the liver with a divalent cation free buffer before 
proteolytic digestion of the matrix with collagenase. This extra step effectively loosens the 
desmosome and hemi-desmosome junctions between the adjacent cells and extracellular matrix. 
Since then the so called two-step collagenase perfusion technique has become the „standard“ 
protocol for hepatocyte isolation.  
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From 1977, several laboratories have reported on the purification and culture of intrahepatic BECs 
from the rat liver after bile duct ligation (Sirica et al. 1990). Intrahepatic BECs represent only about 
3-5% of total cells in the liver, and induction of compensatory proliferating bile ductules by bile 
duct ligation of rat liver can expand BECs population by up to 100 fold and generate sufficient cells 
for research (Sirica et al. 1990). Perfusion of rat liver in situ with digestive enzymes such as 
collagenase generates a heterogeneous mixture of cell types which requires further purification of 
BECs. Several techniques including differential density gradient centrifugation, centrifugal 
elutriation, fluorescence activated cell sorting, and immunological selection methods have been 
used either singly or in combination to produce a population enriched with BECs. The degree of 
enrichment for different procedures is variable ranging from less than 75% to greater than 95% 
(Joplin 1994). 
In 1982, the isolation, in high yield and viability, of human hepatocytes from wedges of liver tissue 
was reported using the adapted two-step rat liver perfusion procedure (Strom et al. 1982). Adult 
human hepatocytes in primary culture can survive for some time in vitro, and have been used for 
metabolic studies and toxicity assays of a variety of chemicals. However, human hepatocytes in 
primary culture normally quickly lose their capacity for differentiated function and have limited 
capacity for replication. Lechner et al (1989) suggested that there was evidence for a „stem“ cell 
population in the adult human liver based on the finding that isolated hepatocytes could grow in 
serum free medium, at least for a limited time period. However, addition of hormones and growth 
factors provides greater growth potential.  
In 1989, Joplin reported by using a monoclonal antibody (anti-HEA) which recognizes a specific 
antigen (human epithelial antigen, HEA) on the surface of BECs to positively purify human 
intrahepatic BECs from a semi-pure differential density centrifugation product (Joplin et al., 1989). 
Human intrahepatic BECs express the hepatocyte growth factor (HGF) receptor, c-Met, and respond 
to HGF. In the growth medium containing HGF, human BECs may sustain proliferation for 3 to 5 
months and permit serial passages (Joplin et al. 1992). Intrahepatic BECs in culture express the 
typical phenotype, such as CK 7, CK 19 and γ-GT, and they also have the epithelial cell markers, 
such as CK 8 and CK 18. Intrahepatic BECs have a great potential to proliferate, but the origin of 
proliferating cells is not totally clear. Although the cells lining in the interior of large and medium 
sized bile ducts have been thought as their origin, it is also suspected that some of them possibly 
originate from the bile ductule, which is the smallest branch of the biliary system and believed to be 
the location of the putative liver progenitor or stem cell. 
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1.5. Aim of the study 
As stated above, more and more investigators have believed that there are some cells with stem cell 
potential in the liver, and they may exist in biliary tree of rodent animal. Oval-like cells were also 
found in a variety of human liver diseases, and it has been suggested that human biliary tree may 
also contain liver stem cells. However, there has been no report to identify this. On the other hand, 
human intrahepatic BECs have a great potential to proliferate in vitro, but the origin of proliferating 
cells is not quite clear. It might contain some putative liver stem cells in human biliary tree. 
In order to identify these hypotheses, human intrahepatic BECs were first isolated and cultured, and 
then characterized with different liver stem cells markers at both mRNA and protein level. Double-
fluorescent immunostaining was used to check whether these cells co-express hepatocyte marker 
and biliary cell marker. The study includes: 1. Isolation and culture of human hepatocytes and 
intrahepatic BECs. 2. Morphological and phenotypic characterization of the cultured cells with 
phase contrast microscope, fluorescence activated cell sorting (FACS), reverse transcription 
polymerase chain reaction (RT-PCR), immunohistochemistry technique. 3. Measurement of 
lidocaine metabolism function of hepatocytes and BECs. 4. Measurement the effect of growth 
factors on the proliferation of BECs. 
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2. MATERIALS AND METHODS 
 
2.1. Materials 
 
2.1.1. Instruments 
Refrigerator 4 °C  Liebherr, Germany 
Refrigerator -20 °C  Kirsch, Bosch, Germany 
Refrigerator -80°C  NUAIR, Zapf instruments, Sarstedt 
Cell culture incubator  Heraeus, Düsseldorf 
Phase contrast microscope  Nikon, TMS, Japan 
Fluorescence microscope  Nikon Elipse  TS100, Japan 
Confocal fluorescence microscope  Olympus BX 60, Japan 
Table centrifuge  Heraeus, Düsseldorf 
  Sigma 3K20, Osterode/Harz 
Masterflex Digital Drive  Cole-pamer instrument Company, Illinois 
Waterbath  Julabo, U3/7, Seelbach 
Cell dissocitaion sieve  Sigma, USA 
Magnetiser  Dynal A.S. Oslo, Norway 
RNA/DNA Calculator  LKB Biochrom, England 
Spektraphotometer PM6  Zeiss, Oberkochen 
GeneAmp PCR system 9600  Pekin Elmer, USA 
Electrophoresis equipment  Biometra PP3000, USA 
Electrophoresis bath  Keutz, Reiskirchen 
DNA-Gelcomb  DNA Subcell, Biorad, München 
Protein-Gelcomb  Mini Protean II, Biorad, München 
Proteintransfectcomb  Fastblot B33, Biometra, Göttingen 
Geldocumentation 
Pipetting-tool 
 Biostep labor & systemtechnic GmbH, 
Jahnsdorf 
Pipettierhilfen  Pipetus, Hirschmann Laboratory, Eberstadt 
Microliterpipette  1-10µl, 10-100µl, 100-1000µl, Eppendorf, 
Hamburg 
  0.1-2µl, Pipetman P2, Abimed, Langenfeld 
Electronic Balance  MP-3000, Chyo, Japan 
  Mettler AT261, Swiss 
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Magnetic stirrer  Combimag RET, IKA-Labortechnik, 
Staufen, i.Br. 
Mini Shaker  MS1, IKA-Labortechnik 
Circular Shaker  KS125, IKA-Labortechnik 
Horizontal shaker  Vibrax-VXR, IKA-Labortechnik, Staufen i. 
Br. 
FACS measure instrument  FACScan, Becton-Dickinson, Heidelberg 
Elisa-measure instrument  LambdaE, MWG-Biotech, Ebersberg 
pH-Meter  pH-Meter 765, Calimatic, Germany 
Cell smear machine  Auto smear CF-12DE, SAKURA 
TDx Analyzer  Abbott Laboratories, Illinois 
 
 
2.1.2. Consumer Material 
Measure cylinder 100, 250, 500, 1000ml  Schott Glaswerke, Mainz 
Beaker glass 250, 400, 600ml  Schott Glaswerke, Mainz 
Erlenmeyer flask  Schott Glaswerke, Mainz 
Sterile pipet 10µl  Greiner, Frickenhausen 
Sterile pipet 100µl, 1000µl  Biozym Diagnostik GmbH, Hess. Oldendorf 
Pipet tips 10µl, 100µl, 1000µl  Eppendorf, Hamburg 
Pipet tips 2µl  Abimed, Langenfeld 
Gel loading tip  Biozym Diagnostik GmbH, Hess. Oldendorf 
Falcon Pipet 2, 5,10, 25, 50ml  Becton Dickinson Labware, NJ, USA 
Centrifuge tube 15, 50ml  Greiner, Frickenhausen 
Vials 0,5 / 1,5 / 2ml  Eppendorf, Hamburg 
96-well Elisa-plate  Costar Europe, Badhoevedrop / NL 
Tissue culture Plates (24 well, 12 well, 6 
well) 
 Greiner, Frickenhausen 
Tissue culture Flasks (25cm2, 75 cm2, 182 
cm2) 
 Greiner, Frickenhausen 
Petri Dishes (60/15mm , 94/16mm, 145/20 
mm) 
 Greiner, Frickenhausen 
Nitrocellulose  Schleicher & Schuell, Dassel 
Cell scraper  Greiner, Frickenhausen 
Millipore Bacterial Filtrator  Molsheim, France 
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Nalgene Filtration Products 100, 500, 1000ml  Nalge Nunc international, New York 
Sterile Specimen Container  Becton Dickinson Labware, NJ, USA 
 
 
2.1.3. Chemical 
 
2.1.3.1. Cell isolation and culture 
Hanks’ Balanced Salt Solution (HBSS) 
without Calcium & Magnesium 
 Biochrom KG, Berlin 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
 PAA, Austria 
DMEM / HAM’s  F-12  PAA, Austria 
PBS with Calcium & Magnesium  Biochrom KG, Berlin 
PBS without Calcium & Magnesium  Biochrom KG, Berlin 
William’s Medium  Biochrom KG, Berlin 
1M HEPES Buffer  Biochrom KG, Berlin 
200mM L-Glutamine  Biochrom KG, Berlin 
10mg/ml Gentamicin  Biochrom KG, Berlin 
4mg/ml Collagen G (From Bovine Calf Skin)  Biochrom KG, Berlin 
Percoll (1. 124g/ml)  Biochrom KG, Berlin 
EGTA  Sigma, Deisenhofen 
MgCL2  Sigma, Deisenhofen 
Tissue Adhesive  Braun, Germany 
Insulin  Sigma, Deisenhofen 
Cholera toxin  Calbiochem 
Hydrocortisone  Sigma, Deisenhofen 
Triiodothyronine  Sigma, Deisenhofen 
HGF  R & D, UK 
EGF  Sigma, Deisenhofen 
10000 units/ml penicillin and  Life Technologies, Karlsruhe 
10000 mg/ml streptomycin   
Fetal Bovine Serum (FBS)  Gibco BRL, Scotland 
Collagenase IA (467 units/mg)  Sigma, Deisenhofen 
Collagenase  IV (449 units/mg)  Sigma, Deisenhofen 
Collagenase XI (1240 units/mg)  Sigma, Deisenhofen 
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TGF-β1  Sigma, Missouri 
0.5g/l Trypsin and 0.2g/l EDTA in HBSS  Sigma, UK 
EDTA  Merck, Darmstadt 
 
2.1.3.2. RT-PCR 
Trizol Reagent  Life Technologies, New York 
Isopropanol  Merck, Darmstadt 
2-Mercaptoethanol  Merck, Darmstadt 
Chloroform  Merck, Darmstadt 
Ethanol 100%  Serva,Heidelberg 
DEPC-treated Water  Ambion 
Total RNA Isolation Reagent  Life Technologies, New York 
RNA Reversetranscription Kit  Promega, USA 
Rneasy mini Kit  Qiagen, Germany 
Taq Polymerase and 10X PCR Buffer  Roche, Manheim 
10mM dNTP  Boehringer, Manheim 
Primers  Carl Roth, Karlsruhe 
Loading buffer  Fermentas, Lithuania 
DNA ladder  Fermentas, Lithuania 
Agarose  Pharmacia, Denmark 
Ethidiumbromide (1mg/ml)  Sigma-Aldrich, Deisenhofen 
 
2.1.3.3. FACS and immunohistochemistry 
Fix & Perm cell permeabilization kit  Dianova, Hamburg 
Formaldehyde 37%  Sigma-Aldrich, Deisenhofen 
Methanol  Roth, Karlsruhe 
Goat serum  Sigma-Aldrich, Deisenhofen 
Pig serum  Nordic, Germany 
Peroxidase Blocking Reagent  DAKO, Denmark 
Aminomethylpropandiol-buffer  Merck, Darmstadt 
Tris-buffer PH 9.7  Merck, Darmstadt 
NaCl  Merck, Darmstadt 
Levamisole  Sigma, Steinheim 
Naphthol-AS-Bi-Phosphat  Sigma, Steinheim 
DMF (Dimethylformamid) Solution  Merck, Darmstadt 
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Neufuchsinlsg 5%  Chroma 
Natriumnitritlsg 4%  Sigma, Steinheim 
Ethylcarbazole  Sigma, Steinheim 
Aceton  Merck, Darmstadt 
Dimethylsulfoxid solution  Merck, Darmstadt 
3% H2O2  Merck, Darmstadt 
Mayer’s Hematoxylin  Merck, Darmstadt 
Glyceringelatine  Merck, Darmstadt 
 
2.1.3.4. Antibodies 
HEA (monoclonal, IgG1)  Progen, Heidelberg 
Cytokeratin 7 (monoclonal, IgG1)  Progen, Heidelberg 
Cytokeratin 8 (monoclonal, IgG1)  Progen, Heidelberg 
Cytokeratin 18 (monoclonal, IgG1)  Progen, Heidelberg 
Cytokeratin 19 (monoclonal, IgG2b)  Progen, Heidelberg 
Cytokeratin 14 (monoclonal, IgG1)  Progen, Heidelberg 
Vimentin (monoclonal, IgG2a)  Progen, Heidelberg 
Desmin (monoclonal, IgG1)  Progen, Heidelberg 
Rabbit anti-human Von Willebrand Factor 
(polyclonal) 
 DAKO, Denmark 
Pan-CK  (monoclonal)  Linaris, Germany 
Fix and Perm Cell Permeablization Kit  Dianova, Hamburg 
ASGPR (monoclonal,  IgG1,k)  Calbiochem, Darmstadt, Germany 
ASGPR (polyclonal)  Eurogentec, Seraing, Belgium 
Alpha1-antitrypsin (monoclonal, IgG2)  Chemicon, Temecula, CA 
Alpha1-antitrypsin (polyclonal)  DAKO, Denmark 
Albumin (monoclonal, IgG2a)  Sigma, Missouri 
AFP (monoclonal, IgG2a)  Sigma, Missouri 
AFP (polyclonal)  Nordic, Germany 
c-kit (monoclonal)  DAKO, Hamburg 
Chromogranin-A (monoclonal)  Linaris, Germany 
Chromogranin-A (monoclonal, IgG1k)  Progen, Heidelberg 
FITC-conjugated Goat anti-mouse IgG  Dianova, Hamburg 
FITC-conjugated Goat anti-rabbit IgG  Dianova, Hamburg 
Goat Anti-Mouse IgG1 (FITC conjugate)  Southern Biotechnology Associates, Inc. 
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Alabama 
Goat Anti-Mouse IgG2a (TXRD conjugate)  Southern Biotechnology Associates, Inc. 
Alabama 
Sheep anti-mouse IgG1 (Fc) coated Dyna 
beads 
 Dynal A.S. Oslo, Norway 
Mono-AP-Goat anti Mouse IgG  DAKO, Hamburg 
Goat anti Rabbit Immunoglobin  Nordic, Germany 
PAP-complex  Nordic, Germany 
 
2.1.3.5. Others 
MTT  Sigma, Deisenhofen 
Lidocaine  Astra GmbH, Wedel 
TDx/TDxFLx Lidocaine Assay kit  Abbott Laboratories, Illinosis 
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2.2. Patients 
As depicted in the next table, diseased liver tissue was obtained from explanted livers after liver 
transplantation (No. 1, 3, 7, 8,9), and normal tissue were obtained from liver resections (No 2, 6 and 
10 to 20) and donor liver (No. 4, 5) when it exceeded the surgical requirement. All of the specimens 
were kindly provided by the Department of General Surgery and Transplantation at this hospital 
(Director: Prof. Dr. med. Dr. h.c. mult. Christoph E. Broelsch). 
Table 2.1 General information of the patients and derived cells 
No. Age (years) Sex Diagnosis Derived cells 
1 1 female Oxaluria BECs 
2 1.5 male hepatoblastoma BECs, 
hepatocytes 
3 1 female Carbamyl-phosphat-synthetase-defect BECs 
4 10 female donor BECs 
5 6 female donor BECs 
6 9 female liver neuroendocrine carcinoma BECs 
7 44 female Autoimmune hepatitis (AIH) BECs 
8 64 female primary biliary cirrhosis (PBC) BECs 
9 55 female primary biliary cirrhosis (PBC) BECs 
10 60 male cholangiocarcinoma BECs 
11 71 female hepatocellular carcinoma hepatocytes 
12 33 female focal nodular hypertrophy hepatocytes 
13 62 female cholangiocarcinoma hepatocytes 
14 45 female focal nodular hypertrophy hepatocytes 
15 71 male metastatic liver carcinoma from colon hepatocytes 
16 72 male metastatic liver carcinoma from rectum hepatocytes 
17 51 male hepatocellular carcinoma hepatocytes 
18 52 female metastatic liver carcinoma from colon hepatocytes 
19 68 male metastatic liver carcinoma from colon hepatocytes 
20 60 male hepatocellular carcinoma hepatocytes 
 
 
2.3. Methods 
 
 
2.3.1. Isolation and culture of human hepatocytes 
Shortly after liver resection, 10-20 g of the normal tissue near the edge of liver was cut in wedged 
shape. The tissue was kept in a sterile beaker containing DMEM and brought from the operation 
room to the cell culture room. Before hepatocyte isolation, the tissue was stored in DMEM at 4 °C 
for less than 5 hours. All procedures were done under aseptic conditions. 
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Perfusion of the liver tissue 
1) The liver tissue was put into one Petri dish (145 mm in diameter). One of the exposed blood 
vessels on the cut surface was carefully selected for efficient perfusion, and cannulated with 
the catheter operated by the Masterflex Digital Drive. The remaining exposed vessels were 
closed by the tissue adhesive. 
2) Firstly, the liver tissue was perfused with 300-400 ml 4°C HBSS (containing 0.002% 
Gentamycin and 0.2M HEPES) to expel the blood inside the liver pieces. The perfused 
HBSS solution in the dish was removed completely before the next step. 
3) Secondly, the liver tissue was perfused with 120ml HBSS containing 0.5mM EGTA. The 
first part of perfused HBSS (about 20 to 40 ml) was discarded, then the tissue was 
continually perfused for 15 minutes. The circulating tube (catheter) was warmed to keep the 
temperature of perfusion solution around 35°C. 
4) Thirdly, the liver tissue was perfused with 120 ml HBSS containing 5 mM CaCL2 and 
0.0625% Collagenase IV. The first part of the perfused HBSS (about 20 to 40 ml) was also 
removed, and then the tissue was continually perfused for 10 to 15 minutes (depending on 
the texture of liver tissue). The perfused enzyme solution was also maintained about 35°C. 
The enzyme solution in the dish was removed completely before next step. 
5) In the end, the capsule of the tissue was cut, and the digested tissue was washed with 4°C 
HBSS and passed through the cell dissociation sieve (mesh 60) to remove the undigested 
connective tissue. The cell suspension was made up to 300ml with HBSS and transferred to 
six 50ml centrifuge tubes. 
Wash of the hepatocytes 
1) The cell suspension was spinned at 300 rpm (30g) for 10 minutes at room temperature. 
2) The supernatant was carefully decanted to avoid the loss of the hepatocytes at the bottom. 
3) 50ml HBSS was added to each tube, and the tube was shaken slightly to wash the cells. 
4) The cell suspension was again spinned at 400rpm (35g) for 8 minutes at room temperature. 
5) Steps 3 to 5 were repeated until the supernatant was clear. 
Plating of hepatocytes 
1) The hepatocyte pellet was pooled into 2 or 3 tubes, and re-suspended with plating medium 
(DMEM/HAM’s F-12 with 10% FCS, 40units/ml penicillin, 40µg/ml streptomycin). 
2) The yield and viability of the hepatocytes was determined with the hemacytometer. The cell 
density was adjusted to 500.000/ml before plating. 
3) The hepatocytes were plated in tissue culture plates that had been coated with 0.5mg/ml 
collagen G. (The well of plate was coated with collagen G for 30 minutes at room 
temperature and then washed with PBS.) For the 24-well plate, the 12-well plate and the 6-
  
 
20 
well plate, each well was plated with 250.000, 500.000 and 1.500.000 of hepatocytes, 
respectively. 
4) The cells were kept in an incubator at 37 °C with 5% CO2. 
5) After 20 to 30 minutes, viable hepatocytes adhered, and the supernatant was removed to 
eliminate the floating dead cells. The medium for the culture was DMEM/HAM’s F-12 
with 2-5% FCS, 40unit/ml penicillin and 40µg/ml streptomycin. 
6) The medium was changed every 24 hours and the growth of hepatocytes was observed 
under phase contrast microscope. 
 
 
2.3.2. Isolation and culture of human intrahepatic BECs 
Normal liver tissue was obtained from liver resection or from liver donors (as stated before). 
Diseased liver tissue was obtained from explanted liver during liver transplantation. The tissue was 
stored in DMEM or UW solution at 4 °C within 36 hour before isolation of BECs. All procedures 
were done under aseptic conditions. 
1) 30-50 g of liver tissue were cut into 2-3 mm3 pieces, and the liver pieces were put into a 
beaker with 45ml PBS (with Ca2+ and Mg2+). 
2) 5 ml of Collagenase IA (10mg/ml) was added into the beaker to give a final concentration 
of 1 mg/ml collagenase IA. 
3) The beaker was placed at 37 °C incubator for 30 to 60 minutes and kept shaking with a 
circular shaker. The duration depended on the texture of the liver tissue. 
4) The enzyme digesting suspension in the beaker was passed through the cell dissociation 
sieve (mesh 40) and kept the undigested tissue. 
5) The undigested liver tissue was cut into even finer pieces. 
6) The filtrated solution was spinned at 2000rpm (550g) for 10 minutes at room temperature. 
The supernatant with collagenase was used to digest the liver tissue again at 37 °C for 15 to 
30 minutes, and the cell pellet was kept in PBS (The PBS used in this and the next steps 
was without Ca2+ and Mg2).  
7) The solution in the beaker was passed through the sieve again and the digested tissue was 
washed in the sieve with PBS. Then the filtrated solution was combined with the solution in 
step 6) and made up to 200 ml with PBS. 
8) The cell suspension was dispensed into four 50-ml tubes, and the tubes were spinned at 
2000 rpm for 10 minutes at room temperature. 
9) The cell pellet was washed with PBS until the supernatant was fairly clear. 
10) The pellet was collected into one tube and re-suspended with 24 ml PBS. 
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11) Eight 15-ml centrifuge tubes with 3ml of 68% Percoll solution (1.04g/ml) on the bottom 
and 3ml of 29% Percoll solution (1.09g/ml) on the top were prepared. 
12) Gently, 3 ml of cell suspension was pipetted onto the top of each Percoll gradient. 
13) The cells were spinned at 2500rpm (800g) for 30 minutes at room temperature. The brake 
of the centrifuge was turned off during the centrifugation. 
14) The top layer of „debris“ was discarded. 
15) The differential band of cells were pipetted into one 50-ml tube and made up to 50ml with 
PBS. 
16) The cells were spinned at 2000rpm for 10 minutes. 
17) The cell pellets were suspended with PBS and transferred to one 15 ml-tube. 
18) The cell pellets were washed with PBS repeatedly until the supernatant was fairly clear. 
19) The cell pellets were re-suspended in 0.45ml PBS in a 15-ml tube and added into 50µl of 
aliquot HEA (2.5µg). 
20) The tube was placed at 37 °C for 30 minutes and shaken every 10 minutes to mix the 
solution. 
21) The tube was made up to 10ml with PBS and spinned at 2000rpm for 10 minutes. 
22) The pellet was re-suspended in 0.5ml cold PBS and 10µl of sheep anti-mouse IgG1 (Fc) 
coated Dyna beads (4×107) were added into it. 
23) The tube was placed at 4 °C refrigerator for 30minutes and shaken occasionally (2 to 5 
times). 
24) The tube was made up to approximately 5ml with PBS and placed in the magnetiser. 
25) After 2 minutes, the supernatant was removed to one 15-ml tube. 
26) The last two steps were repeated two more times and the supernatant was collected into the 
same tube. 
27) The cells binding with the beads were suspended in 5ml plating medium (table 2.2) and 
plated in one 25-cm2 flask coated with collagen G. 
28) The above supernatant was spinned at 2000rpm for 10 minutes, and the cells (not binding 
with the beads) were re-suspended with 5 ml plating medium. Also, these cells were plated 
in one 25-cm2 flask coated with collagen G. 
29) The cells were kept in an incubator at 37 °C with 5% CO2. 
30) When the cells had adhered after about 24 to 72 hours, the medium was changed into 
growth medium (table 2.2). Later the growth medium was changed every 3 days or longer, 
depending on the growth speed of the cells. 
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Table 2.2 Prescription of plating medium and growth medium 
Contents Plating medium Growth medium 
DMEM 45% 47.5% 
Ham’s F12 45% 47.5% 
FCS 10% 5% 
Insulin 5 µg/ml 5 µg/ml 
HGF 0 10 ng/ml 
EGF 10 ng/ml 10 ng/ml 
Cholera toxin 10 ng/ml 10 ng/ml 
Hydrocortisone 2 µg/ml 2 µg/ml 
Triiodothyronine 2 nM 2 nM 
Streptomycin 40 µg/ml 40 µg/ml 
Penicillin 40 units/ml 40 units/ml 
 
 
Passage of BECs 
When BECs were confluent in the flask, they were passaged with the next method. 
1) The medium in the flask was removed completely, and then the cells were washed with 
PBS to get rid of FCS.  
2) 2ml of 0.1g/l trypsin and 0.04g/l EDTA (diluted in 0.1% PBE) was added into one 25-cm2 
flask, and the flask was placed in the incubator (37°C) for about 5 minutes. The process of 
enzymatic digestion was checked under the microscope. When the cells became round and 
detached, the digestion was stopped by adding 2 ml DMEM with 5% FCS. 
3) The cell suspension was collected and spinned at 1400 rpm for 4 minutes. 
4) The cell pellets were re-suspended with plating medium and the number of BECs was 
counted. 
5) The cells were plated in the culture plate or flask at some density according to the aim of 
experiment. 
6) After the cells adhered, the cells were cultured with growth medium. 
 
Freezing and thawing of the BECs 
During passage of BECs, the cells were re-suspended in 1 million per ml freezing medium 
(containing 50% DMEM with F12, 40% FCS and 10% DMSO). The cells were first kept at  –80 °C 
refrigerator and then transferred to liquid nitrogen. For thawing of the cells, the cells in the freezing 
tube was taken out from the liquid nitrogen and thawed at room temperature. Then plating medium 
was used to plate the cells. 
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2.3.3. Fluorescence activated cell sorting (FACS) 
One day after plating hepatocytes, the expression of CK 8, CK 18, vimentin, ASGPR by 
hepatocytes were checked with FACS method. BECs were also checked for the expression of CK 7, 
CK 8, CK 18, CK 19, vimentin, desmin with this method.  
Detachment of the cells (Take the cells plated in the 12-well plate as example) 
1) The medium was removed and the cells were washed with PBS. 
2) 0.5ml of collagenase XI (0.02%) was added into each well and incubated with the cells at 
37°C for 15 minutes. Then 0.5ml of 0.1% PBE was added into each well and incubated for 
another 5 minutes at 37°C.  
3) The solution was pulled up and down with plastic pipette for several times to help detach 
the cells.  
4) The cell suspension was collected into one tube and spinned at 1400 rpm for 4 minutes.  
5) The cells were washed with PBS and divided into several equal parts for staining. 
Staining of the cells (with Fix & Perm cell permeabilization kit) 
1) 100µl of solution A (for fixation) in the kit were taken to fix the cells in the tube at room 
temperature for 15 minutes. 
2) The cells were washed with 2ml PBS (the tube was spinned at 1400 rpm for 4 minutes, and 
the below wash step was the same as this) 
3) 100µl of the first antibody were added into the tube and the tube was vortexed to mix the 
cells with the first antibody. ASGPR (1:100, polyclonal) was diluted in PBS, and CK 7 
(1:3), CK 8 (1:3), CK 18 (1:3), vimentin (1:3) were diluted in solution B (for 
permeablization), The cells were incubated with the primary antibody for 30 minutes at 
4°C. 
4) The cells were washed to remove the remaining first antibody. 
5) 100µl of the second antibody (FITC conjugated goat anti-mouse IgG, 1:40; FITC 
conjugated goat anti-rabbit IgG, 1:100) were added into the tube and the tube was vortexed 
to mix the cells with the second antibody. The incubation time was also 30 minutes at 4°C. 
6) The cells were washed to remove the remaining second antibody. 
7) The cells were re-suspended with 0.5ml of 1% formaldehyde in PBS. 
8) The cells were stored at 4°C in the dark before measurement. 
 
Measurement 
FACScan, Becton-Dickinson was used to measure the result. 
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2.3.4. Indirect immunofluorescence staining 
Hepatocytes, BECs grown in the 24-well plate had been checked with this method. 
Fixation of the cells 
1) The medium in the well was aspirated completely. 
2) The cells were washed 1 time with 4°C PBS for 5 minutes. 
3) 0.25ml methanol that had been pre-cooled to -20 °C was added into each well. 
4) The plate was put in -20 °C refrigerator for 6 minutes. 
5) The methanol was aspirated completely. 
6) The cells were washed 3 times with 4°C PBS for 15 minutes. 
Staining of the cells 
The primary antibodies, their working concentration and incubation time, and the stained cells are 
listed in next table. 
Table 2.3 The primary antibody used for indirect immunofluorescence 
Antibody Dilution Incubation time Stained cells 
HEA ( IgG1) 1:10 1 hour at RT BECs 
CK 7 ( IgG1) 1:3 1 hour at RT BECs 
CK 8 ( IgG1) 1:3 1 hour at RT Hepatocytes, BECs 
CK 18 ( IgG1) 1:3 1 hour at 37°C Hepatocytes, BECs 
CK 19 (IgG2b) 1:3 1 hour at RT BECs 
CK 14 ( IgG1) 1:5 1 hour at RT BECs 
Vimentin (IgG2a) 1:3 1 hour at RT BECs 
Desmin (IgG1) 1:10 1 hour at RT BECs 
ASGPR (IgG1,k) 1:50 1 hour at RT Hepatocytes, BECs 
α1-antitrypsin (IgG2) 1:10 1 hour at RT Hepatocytes, BECs 
Albumin (IgG2a) 1:25 1 hour at RT Hepatocytes, BECs 
Factor VIII* 1:200 1 hour at RT BECs 
          * Polyclonal antibody, the others are all monoclonal antibodies. 
1) PBS in the well was removed completely, and 100µl of 10% goat serum were added into 
each well. The serum was incubated with cells at room temperature (RT) for 15 minutes. 
2) The cells were washed with PBS 3 times for 15 minutes. 
3) 100µl of primary antibody were added into different wells. 100µl of PBS were used to 
replace the primary antibody as the negative control. The incubation time was listed in the 
above table. 
4) The cells were washed 3 times with PBS for 15 minutes. 
5) 100µl of the secondary antibody were added into each well. For primary monoclonal 
antibody, FITC conjugated goat anti-mouse IgG (1:50) was used as the second antibody; 
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for primary polyclonal antibody, FITC conjugated goat anti-rabbit (1:100) IgG was used as 
the second antibody. For the staining of albumin and vimentin, goat anti-mouse IgG2a 
(TXRD conjugated) was also used as the second antibody. 
6) The cells were washed 3 times with PBS for 15 minutes. 
7) The cells were covered with PBS and stored in 4°C refrigerator. The staining result was 
observed under fluorescence microscope. 
 
Double-fluorescent immunostaining 
Goat anti-mouse IgG1 (FITC conjugate) and goat anti-mouse IgG2a (TXRD conjugate) were used in 
this experiment. Monoclonal antibodies against CK 7, CK 8 and CK 18 are all IgG1 subclass, and 
monoclonal antibodies against albumin and vimentin are both IgG2a subclass. The co-expression of 
CK 7 and albumin, CK 7 and vimentin, CK 8 and albumin, CK 18 and vimentin by BECs were 
checked by this method. 
1) The fixation of the cells and decrease of non-specific stain with 10% goat serum was the 
same as above. 
2) Primary antibodies, CK 7 (1:3) and albumin (1:40), CK 8 (1:3) and albumin (1:40), CK 18 
(1:3) and vimentin (1:3), CK 7 (1:3) and vimentin (1:3) were diluted in PBS. 100 µl 
primary antibodies were added into each well of 24-well plate, and 100µl of PBS were used 
to replace the primary antibodies as the negative control. The reaction was incubated at 
room temperature for 30 minutes. 
3) The cells were washed 3 times with PBS for 15 minutes. 
4) Second antibodies, goat anti-mouse IgG1 (FITC conjugate, 1:100) and goat anti-mouse 
IgG2a (TXRD conjugate, 1:100) were diluted in PBS, and 100µl second antibodies were 
added into each of 24-well plate. The reaction was done at room temperature for 30 
minutes. 
5) The cells were washed 3 times with PBS for 15 minutes. 
6) The result was detected under fluoresecent microscope (Olympus BS 51, Japan). 
 
 
2.3.5. Reverse transcription polymerase chain reaction (RT-PCR) 
The expression of albumin mRNA and AFP mRNA by human intrahepatic BECs were checked 
with RT-PCR method. Primary human hepatocytes, HepG2 cell line, Raji cell line were used as 
controls. 
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2.3.5.1. RNA extraction from the monolayer cells 
During the passage of BECs, HepG2 and Raji cells, they were plated in the Petri dish with 60mm in 
diameter for RNA extraction. Freshly isolated hepatocytes were directly plated in the same type of 
Petri dish. 
Homogenization 
1) The medium was removed completely and 1ml Trizol was added into each dish. 
2) The cells were scraped into the Trizol with a sterile cell scraper. 
3) The cells in Trizol were transferred to an autoclaved 1.5ml vial (microfuge tube). 
Phase Separation 
1) The cells were incubated in Trizol at room temperature for 5 minutes. 
2) 0.2ml chloroform was added into the vial and it was shaken vigorously by hand for 15 
seconds. 
3) The reaction was incubated at room temperature for 2-3 minutes. 
4) The vial was centrifuged at 12 000 g for 15 minutes at 4°C. 
5) The upper (colourless) phase was pipetted off and put in new Eppis on ice. 
RNA Precipitation 
1) 0.5ml isopropanol was added into the Eppis and the Eppis was vortexed shortly. 
2) The reaction was incubated on ice for 10 minutes. 
3) The vial was centrifuged at 12 000 g for 10 minutes at 4°C. 
4) The supernatant was removed immediately by pouring it out slowly in one motion and the 
last drop was blotted with paper tissue. 
RNA Wash 
1) The vial was put on ice and 1ml ice cold 75% ethanol was added into it. (The 75% ethanol 
was made with 100% ethanol and DEPC-treated H2O.) The vial was vortexed shortly. 
2) The vial was centrifuged at 7500 g for 5 minutes at 4°C. 
3) The supernatant was removed as before and the vial was put on ice.  
4) The vial was centrifuged again at 7500 g for 1 minute at 4 °C and then put on ice. 
5) The rest of the supernatant was removed with an autoclaved 10ul gel-loading tip. 
6) The RNA was dissolved in 50µl of DEPC-treated H2O and the RNA solution was freezed at 
-80°C. After one freeze-thaw cycle, the RNA would be in solution. 
RNA cleanup (with Rneasy Mini Kit) 
1) The sample was adjusted to a volume of 100 µl with RNase-free water, and 350 µl of 
Buffer RLT (with 10% ß-Mercaptoethanol) was added into it. The solution was mixed 
thoroughly. 
2) 250µl of ethanol (100%) were added into the lysate and they were mixed well by pipetting. 
  
 
27 
3) The sample (700 µl) was applied to a Rneasy mini spin column sitting in a collection tube, 
and the tube was centrifuged for 15 seconds at 8000 g. 
4) The Rneasy column was transferred into a new 2-ml collection tube, and 500µl of buffer 
RPE were added onto the column. The tube was centrifuged for 15 seconds at 8000 g to 
wash the RNA. 
5) 500µl of buffer RPE were pipetted onto the Rneasy column, and the tube was centrifuged 
for 2 minutes at 14.000 rpm to dry the Rneasy membrane. 
6) The Rneasy column was transferred into a new 1.5ml collection tube, and 30µl of RNase-
free water were pipetted directly onto the Rneasy membrane. The tube was centrifuged for 
1 minute at 10.000 rpm to elute the RNA. 
RNA calculation 
The purity, ratio of OD260/OD280 and concentration of isolated total RNA were measured with 
RNA/DNA Calculator (LKB Biochrom, England). 
 
2.3.5.2. Reverse transcription 
Table 2.4 The composition of reverse transcription 
 Negative Control reverse transcription 
25mM MgCL2 4µl 4µl 
RT 10 X Buffer 2µl 2µl 
10mM dNTP 2µl 2µl 
RNAsin 0.5µl 0.5µl 
0.5µg/µl Oligo (dT)15 1µl 1µl 
20units/µl AMV-RTase 0 0.75µl 
DEPC treated water make up to 20µl make up to 20µl 
 
1) 2µg of total RNA were denatured in the Eppis at 70°C for 10 minutes 
2) The vial with RNA was directly put on ice for no less than 5 minutes. 
3) The vial was centrifuged at 4°C for 1 minute to let the evaporated water under the lid go to 
the bottom. 
4) A reaction to synthesize the first strand of cDNA from the mRNA in total RNA was set up 
as below table. 
5) The reaction was incubated at 42°C for 60 minutes. 
6) The AMV-RTase was inactivated at 95°C for 5 minutes. 
7) The Eppis was cooled to room temperature and centrifuged to let the evaporated water 
under the lid go to the bottom. The cDNA was stored in the vial at -20°C. 
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2.3.5.3. PCR 
The sequence of the primers for GAPDH, albumin and AFP were listed in next table. 
The 2.5 The sequence of the primers used in this experiment 
Primers Sequence Position in the cDNA 
GAPDH-F* 5’-CAA CTA CAT GGT TTA CAT GTT-3’ 120 - 140 
GAPDH-R# 5’-ACT TGT GGT CAT GAG TCC TTC-3’ 514 - 534 
Albumin-F 5’-GTG TTT CGT CGA GAT GCA CAC-3’ 60 - 80 
Albumin-R 5’-AAG TTC ATC GAG CTT TGG CAA-3 606 - 626 
AFP-F 5’-ACA CTG CAT AGA AAT GAA TAT-3’ 57 - 77 
AFP-R 5’-TTC AGC TTT GCA GCA AGA TGG-3’ 567 - 587 
          * Forward Primer  # Reverse Primer 
PCR  
A PCR reaction to amplify the targeted mRNA using cDNA as template was set up as below. 
Table 2.6 The compositions of PCR 
 Negative Control RT-PCR 
Template 2µl cDNA 2µl cDNA 
10 X PCR Buffer 5µl 5µl 
Forward primer (2µM) 10µl 10µl 
Reverse primer (2µM) 10µl 10µl 
Taq polymerase (5units/µl) 0.25 µl 0.25 µl 
DNase free water make up to 50µl make up to 50µl 
 
PCR Conditions 
Table 2.7 The procedures for second stage of PCR 
Products Denaturation Annealing Extension Number of cycles 
GAPDH 94°C/60 seconds 60°C/60 seconds 72°C/60 seconds 25 
Albumin 94°C/60 seconds 60°C/60 seconds 72°C/60 seconds 35 
AFP 94°C/60 seconds 60°C/60 seconds 72°C/60 seconds 35 
 
PCR was operated with GeneAmp PCR system 9600 (Pekin Elmer), and the process of PCR 
included 3 stages: 
1) The first stage of PCR: Denaturation at 94°C for 5 minutes. 
2) The second stage of PCR was as below table. 
3) The third stage of PCR: Extension at 72°C for 10 minutes. 
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2.3.5.4. Electrophoresis 
1) 10µl PCR solution were taken and mixed with 2µl six-times loading buffer 
2) The PCR products were run in 1% agarose gel (in TBE) containing 1mg/ml ethidium 
bromide. 
3) The results were observed under the gel documentation equipment. 
 
2.3.6. Immunohistochemistry 
Several lines of cultured BECs in the flasks were detected the expression of Pan-CK, AFP, α1-
antitrypsin, c-kit, chromogranin-A with immunohistochemistry technique (This part was done under 
the kind guide of Dr. med. Olaf Dirsch). 
Cell smear preparation (with the help of Frau Birgit Linker) 
The cells were detached with 0.2% PBE (incubation at 37°C for 10 minutes) or with the cell 
scraper, and single cells were collected onto a glass slide using a Cytospin cytocentrifuge. The cells 
on the slides were fixed with 95% ethanol. Heat-induced epitope retrieval was performed by boiling 
the slides with specimen in 97.7°C water for 40 minutes and cooling at room temperature for 20 
minutes. Antibodies used in these experiments were listed in next table. 
Table 2.8 The primary antibodies used for immunohistochemistry 
Antibody Dilution Duration 
Pan-CK* ready to use 2hr. at 37°C 
AFP* 1:100 30min. at RT 
α1-antitrypsin* 1:50 30min. at RT 
c-kit# 1:50 30min. at RT 
chromogranin-A# ready to use 2hr. at RT 
         *polyclonal antibody  # monoclonal antibody 
 
2.3.6.1. Powervision detection system 
Pan-CK, c-kit and chromogranin-A were stained with Powervision detection system (with the help 
of Frau Ute Möser, Frau Michaela Kasimir and Frau Renate Kern). 
Procedure of stain  
1) The slides were taken out of the ethanol solution, and washed with “DAKO wash buffer” 
(The below wash buffer was the same as this). 
2) The sample was incubated with “Background Reducing Components” at room temperature  
(RT) for half an hour. 
3) The slides were washed 3 times for 15 minutes. 
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4) The first antibody diluted in Tris-buffered saline (TBS, PH 7.4) was added onto the sample 
and the incubation time was listed in the above table. TBS was used instead of the first 
antibody as negative control.  
5) The slides were washed 3 times for 15 minutes 
6) The second antibody (Powervision Mono-AP-Goat anti Mouse Ig G) was added to the 
sample and incubated at RT for 1 hour. 
7) The slides were washed 3 times for 15 minutes 
8) The colour-developing solution was prepared as below. 
(1) Solution I was composed of 18ml Aminomethylpropandiol-buffer, 50ml 0.05mol Tris-
buffer (PH 9.7), 0.6g NaCL (0.15mol) and 28mg Levamisole. The first two solutions 
were mixed and then they were added into the beaker with NaCL and Levamisole 
(stirring them to promote dissolution). 
(2) Solution II was composed of 35mg Naphthol-AS-Bi-Phosphat in 0.5ml DMF 
(Dimethylformamid) solution. 
(3) Solution III was composed of 8 drops Neufuchsinlsg (5%) and 20 drops 
Natriumnitritlsg (4%). 
(4) First solution III was mixed with solution I, and then they were mixed with solution II. 
pH was adjusted to 8.7 with 2N HCL. 
(5) The colour developing solution was passed through the filtering paper. 
9) The colour was developed as below: 
(1) The slides were incubated in the above solution at RT for 20 min. 
(2) The colour developing solution was decanted and the slides were washed with running 
cold water. 
(3) The sample was counterstained with Mayer’s Hematoxylin for 10 to 20 seconds  
(4) The slides were first washed with warm water, and then washed with cold water. 
(5) The slide was mounted with the coverslip, and one drop of glyceringelatine was added 
between the sample and the coverslip. 
 
2.3.6.2. Peroxidase-anti-peroxidase (PAP) detection system 
AFP and alpha1-antitrypsin were stained with PAP detection system (with the help of Frau Ute 
Möser, Frau Michaela Kasimir and Frau Renate Kern). 
Procedure of staining 
1) The sample was incubated with peroxidase-blocking reagent (DAKO, Denmark) for 5 
minutes. 
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2) The slides were washed with “DAKO wash buffer” for 5 minutes. (The below wash step 
was the same as this). 
3) The samples were incubated with normal pig serum (1:20) for 15 minutes. 
4) The slides were washed. 
5) The sample was incubated with the first antibody. TBS was used instead of the first 
antibody as the negative control. The incubation time was listed in above table. 
6) The slides were washed. 
7) The sample was incubated with “goat anti-rabbit immunoglobin” (1:40) for 30 minutes at 
room temperature. 
8) The slides were washed. 
9) The sample was incubated with PAP-complex (1:100) at room temperature for 30 minutes. 
10) The slides were washed. 
11) Preparation of colour-developing solution: 25mg 3-amino-9 ethylcarbazole were diluted in 
5ml Aceton and 5ml Dimethylsulfoxid solution and then 40ml distilled water and 0.2ml 3% 
H2O2 were added into them. 
12) The colour was developed as below: 
(1) The colour-developing solution was filtrated. 
(2) The slides were incubated inside the solution for 10 minutes. 
(3) The slides were washed with cold water. 
(4) The sample was counterstained with Mayer’s Hematoxylin for 15 seconds.  
(5) First the slides were washed with warm water for 3 times, second with cold water for 3 
times. 
(6) The slide was mounted with the coverslip, and one drop of Glyceringelatine was added 
between the sample and the coverslip. 
 
2.3.7. Metabolism of lidocaine by human hepatocytes and intrahepatic BECs 
In order to detect whether the proliferating BECs have activity of cytochrome P450 
monooxygenase, lidocaine metabolism test was performed (with the help of Miss Mechthild Beste). 
The experiments were repeated 6 times in No.3 BECs line. Primary hepatocytes (On day 2 after 
culture) were checked at the same time. 
Process of lidocaine metabolism test on the BECs and hepatocytes 
1) Lidocaine was added into the culture medium to get an initial concentration of 5nM. 
2) 1, 8, 24 hours later, 220µl supernatant were separately collected. Each time point was 
repeated 6 times. 
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3) The concentration of lidocaine in the supernatant was measured with TDx Analyzer 
machine (Fluorescence Polarization Immunoassay, FPIA). 
 
2.3.8. Study of FCS, EGF, HGF, TGF-β1 and human serum from liver resection patient on 
proliferation of the BECs. (MTT Method) 
In order to analyze the growth regulation of BECs by growth factors, the effect of FCS (1 % and 
10%), EGF (10 ng/ml), HGF (10 ng/ml) and TGF-β1 (10 ng/ml) on the proliferation of BECs was 
studied. The concentrations of EGF and HGF were the same as in the growth medium, and 10 ng/ml 
TGF-β1 was reported to be able to inhibit the proliferation of most epithelial cells in vitro. The 
human serum from the liver resection patient (Hepatocellular carcinoma patient) on the proliferation 
of the BECs was also checked. 
During passage, the cells were plated in the 24-well plate coated with collagen G. Each well was 
plated 10.000 cells. The experiment was started one day after the plating. The cells were washed 
with PBS for 2 times, then the basic medium containing different factors were added. 
The basic medium was Williams medium which contained 2mM glutamine, 0.02M HEPES, 5µg/ml 
insulin, 2µg/ml hydrocortisone, 40units/ml penicillin and 40µg/ml streptomycin. The human serum 
was taken just before the liver resection (day 0) and on day 1, 2, 3, 4 and 5 after operation. Each 
determination was performed 6 times. 
MTT 
1) After 24 hours, MTT method was used to detect the growth of the cells as below: 
2) 110µl of MTT (4mg/ml) were added into each well (containing 1ml medium) in the 24-well 
plate. 
3) Four hours later, the supernatant was removed, and 250µl of DMSO were added into each 
well to solubilize the formazan dye converted from MTT by the cells. 
4) Five minutes later, the plate was shaken to make the solution homogenous. The dye was 
quantitated with an ELISA plate reader at wavelength of 550nm-690nm. 
 
2.3.9. Statistical analysis 
One-way ANOAVA with SPSS software (version 8.0) for windows was employed to compare the 
mean of different groups. 
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3. RESULTS 
 
3.1. Isolation, culture and characterization of human hepatocytes 
With the two steps of EGTA and collagenase perfusion methods, hepatocytes were stably isolated 
from eleven different liver tissues. The viability of freshly isolated hepatocytes was between 65-
85% in these experiments. Freshly isolated hepatocytes are round and singly distributed. About 20 
minutes after plating, hepatocytes adhered to the bottom of the culture plate coated with collagen G. 
Around 24 hours after plating, hepatocytes were confluent and presented typical polygonal shape 
(figue3.3). Hepatocytes were able to survive more than 2 to 4 weeks in culture. 
Using FACS analysis, it was found that cultured hepatocytes expressed high level of CK 8, CK 18, 
ASGPR and low level of vimentin on the first day after plating (figure 3.1). Lidocaine metabolism 
experiments indicated they were capable of metabolizing lidocaine (figure 3.28). Indirect 
immunofluorescence staining identified that they were positive for CK 8, CK 18, albumin, ASGPR 
and alpha1 anti-trypsin (figure 3.4 and 3.5). 
 
3.2. Isolation and culture of human intrahepatic BECs 
Table 3.1 Summary of isolation and culture of intrahepatic BECs from 10 liver tissues 
No. Liver tissue digestion time Cell lines passage times proliferating time 
1 36 gram 60/20 minutes 1BECs 12 18 weeks 
2 40 gram 30/30 minutes 2BECs 11 12 weeks 
3 43 gram 30/20 minutes 3BECs 10 12 weeks 
4 50 gram 30/20 minutes 4BECs 7 7 weeks 
5* 43 gram 50/0 minutes 5BECs 3 4 weeks 
6* 20 gram 60/0 minutes 6BECs 3 4 weeks 
7 37 gram 70/0 minutes 7BECs 3 4 weeks 
8 46 gram 60/0 minutes 8BECs 3 4 weeks 
9 50 gram 60/40 minutes 9BECs 3 4 weeks 
10# 46 gram 60/0 minutes 9BECs 0 1 week 
          * The cells were freezed after the last passage. 
          # The cells were fixed at 1 week for experiment and stopped growing. 
Isolation of human intrahepatic BECs included three main steps. The first step was to digest diced 
liver pieces with collagenase and to get liver cell suspension. The second step was to obtain 
nonparenchymal cells (NPCs) by differential density centrifugation. The third step was to purify 
BECs from NPCs with immunomagnetic separation method (anti-HEA). The above table 
summarized the results of isolation and culture of  intrahepatic BECs from 10 different sources of 
liver tissues. 
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Freshly isolated BECs were round and formed clusters. Under contrast microscope, magnetic Dyna 
beads could be seen on the surface of BECs (picture3.6). From PBC and AIH liver tissues, the yield 
of BECs was very high, and the cells rapidly adhered and began to proliferate. About 12 hours after 
plating, many islands of BECs appeared (picture3.7). Therefore these cells were cultured with the 
growth medium (containing HGF) on the first day after plating. Some primary BECs were found 
still bound with the magnetic beads until they were passaged. The BECs from PBC and AIH liver 
tissue grew fast and became confluent in one 25cm2 flask in about 1 week after plating. However, 
after the passage, the growth speed of BECs decreased obviously. 
On the other hand, the yield of BECs from children liver tissues (No. 1, 2, 3, 4) was lower, and it 
took about 72 hours for most of the BECs to adhere to the wall of culture flask.  The BECs formed a 
few small islands. After the cells were cultured with growth medium containing growth factors, the 
BECs began to proliferate faster. On the average, the first passage of BECs from the children liver 
tissues was done on the 11th day after culture. After passage, the BECs still proliferated as fast as 
before until 7 to 12 weeks after culture. 
The viability of BECs after freezing and thawing was about 90%, and they kept the growth potential 
as usual and specific phenotype (see below). 
 
3.3. Characterization of human intrahepatic BECs 
3.3.1. Morphology 
Under phase contrast microscope, primary BECs were small and had oval shape. After passage, 
most BECs from PBC or AIH liver tissues became large and round, with many vacuoles in the 
cytoplasm. However, the BECs from children’s liver tissues kept small and oval shape until they 
stopped proliferation (picture3.8). Moreover, hepatocyte-like BECs were found in the passaged 
BECs in this experiment, when some BECs became nearly confluent and the culture medium had 
been maintained for some time. These BECs had polygonal shape that was similar to hepatocytes’, 
and they could survive for more than 4 weeks before the culture medium was changed (picture3.9). 
 
3.3.2. FACS 
Using FACS analysis, it was found that all isolated BECs in the culture expressed CK 7, CK 8, CK 
18 and CK 19, while they did not express desmin. In primary BECs, the positive rate of vimentin 
was very low. However, in the proliferating and passaged BECs, the positive rate of vimentin 
increased. At the same time, most of the BECs were still positive for CK 19 (picture3.2, table 3.2). 
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3.3.3. Indirect immunofluorescence staining 
Indirect immunofluoresecence staining was in agreement with the results of FACS. All of the BECs 
in culture expressed CK 7, CK 8, CK 18, CK 19, while did not express desmin, factor VIII and 
ASGPR. HEA was positive in the primary BECs and negative in the late passaged BECs (after 
culture for 3 to 4 weeks). Vimentin expression was seen after BECs were passaged. (picture3.10-
14). Albumin and α1-antitrypsin were negative in the primary BECs (No. 7 and No. 10 BECs lines 
were stained ) (picture3.15). However, they were positive after the BECs were passaged, and this 
included the BECs from the 1st to the 11th passage (picture3.18). CK 14 is believed to be the one of 
the liver progenitor cell markers present between 8 and 14 weeks‘ gestation during liver 
development. In this study, CK 14 positive BECs were not found (table 3.2). 
Table3.2  Summary of FACS and indirect immunofluorescence analysis of the BECs 
Antibodies Primary BECs Passaged BECs 
HEA + -  
CK 8 + + 
CK 18 + + 
CK 7 + + 
CK 19 + + 
CK 14 - - 
Vimentin - + 
Desmin - - 
ASGPR - - 
α1-antitrypsin - + 
Albumin - + 
Factor VIII - - 
 
 
3.3.4. Double-fluorescent immunostaining 
In order to identify the cell origin of albumin and vimentin positive cells, double-fluorescent 
immunostaining was used in this experiment. The primary monoclonal antibodies of CK 7, CK 8 
and CK 18 are all IgG1 subclass, and FITC conjugated goat anti-mouse IgG1 was used as their 
second antibodies. The positive cells for staining of these three antibodies present green colour. 
While the primary antibodies of albumin and vimentin are both IgG2a subclass, and TXRD 
conjugated goat anti-mouse IgG2a was used as their antibodies. The positive cells for staining of 
albumin or vimentin present red colour. The cells positive for both of IgG1 subclass and IgG2a 
subclass present yellow colour under fluoresent microscope. 
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In the stained BECs (3BECs), most cells were both CK 7 and albumin positive, both CK 8 and 
albumin positive, both CK 7 and vimentin positive, and both CK 18 and vimentin positive 
(picture3.19-21). However, some BECs were only positive for CK 7 (picture3.19). This line of 
BECs was freezed on day 40 (the 3rd passage) after isolation and culture. The BECs were stained on 
day 4 after thawing.  
 
3.3.5. Immunohistochemistry 
Using immunohistochemistry technique, it was found that all stained BECs were strongly positive 
for Pan-CK, and this identified their epithelial origin (picture3.22).  BECs from No. 2, 3, 4, 7 liver 
tissues were found to express AFP, c-kit, chromogranin-A and α1-antitrypsin, which are the 
markers of liver stem cells. According to the positive rate of the stained cells, the result was defined 
as − (negative), + (0-25% positive), ++ (25-50% positive), +++ (50-100% positive). The next table 
summarized the results of the immunohistochemistry. 
Table 3.3 The results of the immunohistochemistry of several BECs lines 
Cell lines Passage AFP c-kit Chromogranin-A α1-antitrypsin Pan-CK 
2BECs 10 ++ NE* 
− NE NE 
3BECs 2 and 5 ++ + + NE +++ 
4BECs 3 and 4 ++ + + + +++ 
7BECs 0 ++ ++ NE NE NE 
           *NE: Not Examined. 
AFP expression was seen in all stained BECs, and in some cases most of the cells were strongly 
positive, including the 10th passage of 2BECs, the 3rd and 4th passage of 4BECs, and freshly isolated 
cells of 7BECs. It is worthwhile to point out that 4BECs line derived from a 10 years old donor 
normal liver tissue. C-kit, chromogranin-A and α1-antitrypsin were also positive in most of the 
stained BECs samples(picture3.23-26). 
 
3.3.6. RT-PCR 
RT-PCR was used to detect the mRNA expression of albumin and AFP in No. 1, 2, 3, 4 cell lines. It 
was found that all these BECs lines expressed albumin mRNA (567bp) in the whole period of 
culture. AFP mRNA (531bp) was detected in the No. 2, 3, and 4 cell lines. It is also worthwhile to 
mention that the 9th passage of No. 2 BECs line was still positive for AFP mRNA. Primary 
hepatocytes were positive for albumin mRNA and negative for AFP mRNA. HepG2 cells were both 
positive for albumin mRNA and AFP mRNA. Raji cells were both negative for albumin mRNA and 
AFP mRNA in this experiment. Detection of GAPDH mRNA was served as the normalization 
(pictures3.27). 
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3.4. Metabolism of lidocaine by human hepatocytes and intrahepatic BECs 
Six experiments were done to check the metabolism of lidocaine by BECs and hepatocytes. After 
the lidocaine was added into the culture medium, its concentration in the supernatant of the BECs 
kept unchanged with the time. While in the supernatant of hepatocytes, lidocaine concentration 
decreased obviously from 1 hour later (picture3.28). 
 
 
3.5. FCS, EGF, HGF, TGF-β1, the serum of hepatectomy patient on the proliferation of BECs.  
Using the MTT method to measure the growth of BECs, it was found that FCS (10 %), EGF (10 
ng/ml) and HGF (10 ng/ml) separately promoted the proliferation of the BECs, while FCS (1 %) 
and TGF-β1 (10 ng/ml) had no obvious effect on their proliferation (picture3.29). 
The human serum (5 %) from the 1st to the 5th day after liver resection enhanced significantly the 
proliferation rate of the BECs (P is less than 0.01 in all five time point), and this effect was most 
obvious in serum from the 2nd day after liver resection (picture3.30). 
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Figure 3.1  FACS analysis of primary hepatocytes on day 1 after culture 
The expression of CK 8, CK 18, ASGPR was very high in the hepatocytes, while the expression of 
vimentin was very low. 
CK 8 
CK 18 
Vimentin 
ASGPR 
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Figure 3.2  FACS analysis of BECs (No. 1) at the 6th week after culture 
The expression of CK 19 was still very high after the BECs were cultured for 6 
weeks. However, the expression of vimenin was also high at this time. 
Negative 
CK 19 
Vimentin 
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Figure 3.3  Phase-contrast micrographs of primary hepatocytes on day 2 after culture (100 X) 
Hepatocytes were confluent and had typical polygonal shapes. 
 
 
 
 
 
 
Figure 3.4  Indirect immunofluorescent staining of primary hepatocytes with the alpha1-
antitrypsin antibody 
The hepatocytes were stained on day 2 after culture (100X). FITC conjugated goat anti-mouse IgG 
was used as 2nd antibody. Positive cells presented green colour, and there were some non-specific 
stainings on the top of hepatocytes. 
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Figure 3.5  Indirect immunofluorescent staining of primary hepatocytes  with CK 8 antibody 
The hepatocytes were stained on day 2 after culture (100X). FITC conjugated goat anti-mouse IgG 
was used as 2nd antibody. Positive cells presented green colour, and there were some non-specific 
stainings on the top of hepatocytes. 
 
 
 
 
 
 
Figure 3.6  Phase-contrast micrograph of freshly isolated BECs (100 X) 
BECs (No. 7) were white and round, forming clusters. Dyna beads were round and black, located on 
the surface of the cells. 
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Figure 3.7  Phase-contrast micrograph of BECs on day 1 after culture (100 X) 
BECs (No. 9) had adhered, proliferated and fromed an island. Dyna beads were on the surface of 
BECs. 
 
 
 
 
 
 
Figure 3.8  phase-contrast micrograph of passaged BECs (100 X) 
The BECs (No.4) still had small and oval shape in the 3th week after culture. 
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Figure 3.9  phase-contrast micrograph of hepatocyte-like cells in passaged BECs (100 X) 
In the 5th week after culture, the BECs (No.4) were confluent and some had polygonal shape. 
 
 
 
 
 
 
 
Figure 3.10  Indirect immunofluorescent staining of BECs with anti-HEA (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. As HEA is located on the surface of the 
cells and the cell density was very high, the shape of BECs was not clear and the positive cells 
(green) formed net-like structure. FITC conjugated goat anti-mouse Ig G was used as the 2nd 
antibody. 
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Figure 3.11  Indirect immunofluorescent staining of BECs with CK 7 antibody (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. CK 7 is the specific marker of BECs. 
FITC conjugated goat anti-mouse IgG was used as the 2nd antibody. Positive cells presented green 
colour. 
 
 
 
 
 
 
Figure 3.12  Indirect immunofluorescent staining of BECs with CK 19 antibody (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. CK 19 is also the specific marker of 
BECs. FITC conjugated goat anti-mouse IgG was used as the 2nd antibody. Positive cells presented 
green colour. 
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Figure 3.13  Indirect immunofluorescent staining of BECs with CK 8 antibody (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. CK 8 is the specific marker of epithelial 
cells. FITC conjugated goat anti-mouse IgG was used as the 2nd antibody. Positive cells presented 
green colour. 
 
 
 
 
 
 
Figure 3.14  Indirect immunofluorescent staining of BECs with CK 18 antibody (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. CK 18 is also the specific marker of 
epithelial cells. FITC conjugated goat anti-mouse IgG was used as the 2nd antibody.  Positive cells 
presented green colour. 
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Figure 3.15  Indirect immunofluorescent staining of BECs with vimentin antibody (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. Vimentin is negative in this primary 
BECs. Vimentin is the marker of mesenchymal cells. However, biliary cells in developing liver are 
positive for vimentin from 9 to 36 weeks of gestation. FITC conjugated goat anti-mouse IgG was 
used as the 2nd antibody. 
 
 
 
 
Figure 3.16  Indirect immunofluorescent staining of BECs with albumin antibody (100 X) 
The BECs (No. 7) were stained on the 3rd day after culture. Albumin is negative in this primary 
BECs. Albumin is the maker of hepatocyte and liver stem cell. FITC conjugated goat anti-mouse 
IgG was used as the 2nd antibody. 
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Figure 3.17  Indirect immunofluorescent staining of BECs with vimentin antibody (IgG2a)  
                      (100 X) 
The BECs (No. 3) were freezed on day 40 after culture, and they were stained on day 4 after 
thawing. TXRD conjugated goat anti-mouse IgG2a antibody was used as the 2
nd antibody. Positive 
cells presented red colour. 
 
 
 
 
Figure 3.18  Indirect immunofluorescent staining of BECs with albumin antibody (IgG2a)  
                      (100 X) 
The BECs (No. 3) were freezed on day 40 after culture, and they were stained on day 4 after 
thawing. TXRD conjugated goat anti-mouse IgG2a antibody was used as the 2
nd antibody. Positve 
cells presented red colour. 
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Figure 3.19  Double immunofluoresent staining of BECs with CK 7 (IgG1) and albumin (Ig 
G2a) antibodies  
The BECs (No. 3) were freezed on day 40 after culture, and they were stained on day 4 after 
thawing. FITC conjugated goat anti-mouse IgG1 antibody was used as the 2
nd antibody for CK 7 
(green colour, curved arrow), and TXRD conjugated goat anti-mouse IgG2a antibody was used as  
the 2nd antibody for albumin ( red colour, vertical arrow). Both CK 7 and albumin positive cells 
present yellow colour (straight arrow)  
 
 
 
Figure 3.20  Double immunofluoresent staining of BECs with CK 8 (IgG1) and albumin 
(IgG2a) antibodies  
The BECs (No. 3) were freezed on day 40 after culture, and they were stained on day 4 after 
thawing. FITC conjugated goat anti-mouse IgG1 antibody was used as the 2
nd antibody for CK 8 
(green colour), and TXRD conjugated goat anti-mouse IgG2a antibody was used as the 2
nd antibody 
for albumin (red colour). Both CK 8 and albumin positive cells present yellow colour. Most cells 
were both positive in this field. 
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Figure 3.21  Double immunofluorescent staining of BECs with CK 18 (IgG1) and vimentin 
(IgG2a) antibodies  
The BECs (No. 3) were stained on the 6th week after culture. FITC conjugated goat anti-mouse IgG1 
antibody was used as the 2nd antibody for CK18 (green colour, straight arrow), and TXRD 
conjugated goat anti-mouse IgG2a antibody was used as the 2
nd antibody for vimentin ( red colour). 
Both CK 18 and vimentin positive cells present yellow colour. Most cells were both positive in this 
field. 
 
 
 
 
 
Figue 3.22  Immunohistochemistrical staining of BECs with pan-CK antibody (100X) 
Pan-CK is the marker of epithelial cell. The BECs (No. 4) were stained in the 5th week after culture. 
All the cells are positive (red colour, PAP). 
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Figue 3.23  Immunohistochemistrical staining of BECs with c-kit antibody (100X) 
c-kit is the receptor of stem cell factor and is expressed in ductal plate (primitive biliary cell) in 
developing liver. The expression of c-kit is also found in oval cells. The BECs (No. 4) were stained 
in the 5th week after culture. Some cells were positive. (red in cytoplasm, straight arrow; 
Powervision) 
 
 
 
 
 
Figue 3.24  Immunohistochemistrical staining of BECs with chromogranin-A antibody (100X) 
Chromogranin-A is expressed by reactive bile ductule and oval-like cells in diseased liver. The 
BECs (No. 4) were stained in the 5th week after culture. Some cells were positive (red in cytoplasm, 
Powervision). 
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Figue 3.25  Immunohistochemistrical staining of BECs with AFP antibody (100X) 
AFP is the marker of tumoral hepatocyte and liver stem cell. The BECs (No. 4) were stained in the 
5th week after culture. Most cells in this field were positive (red colour, PAP). This BECs line was 
derived from a 10 years old donor liver tissue. 
 
 
 
 
 
 
Figue 3.26  Immunohistochemistrical staining of BECs with alpha1-antitrypsin antibody 
(100X) 
Alpha1-antitrypsin is the marker of hepatocyte and liver stem cell. The BECs (No. 3) were stained 
in the 7th week after culture. Some cells were positive (red colour, straight arrow; PAP). 
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Albumin RT-PCR products                                               AFP RT-PCR products 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GAPDH RT-PCR products 
 
567 bp 
531 bp 
415 bp 
 M   1     2     3     4    5    6     7     8 
 M     1     2     3     4     5     6      M   1     2     3     4    5    6     7     8 
Figure 3.27  RT-PCR Products: 
 
M: DNA ladder; 1: primary hepatocytes; 2: 
Hep G2 cells; 3: Raji cells; 4: No. 3 BECs, in 
the 5th week after culture. 5: No. 4 BECs, in the 
5th week after culture.6: No. 2 BECs, in the 8th 
week after culture. 7. No. 8 BECs, in the 1st 
week after culture. 8. No. 1 BECs, in the 6th 
week after culture. 
  
 
53 
0
0,2
0,4
day 0 control TGF-ß1 EGF HGF 1%FCS 10%FCS
O
D
 (
55
0-
69
0n
m
)
day 0
24 hour
0
1
2
3
4
5
6
0 1hr 8hr 24hr
L
id
o
ca
in
e
 c
o
n
ce
n
tr
a
tio
n
 (
µ
M
) hepatocytes
BECs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28  The change of lidocaine concentration in the supernatant of the cells with time 
Lidocaine was added into the culture medium at the concentration of 5µM. One hour, 8 hours and 
24 hours later, the supernatant was collected and the concentration of lidocaine was measured with 
fluorescence polarization immunoassay method. The concentration of lidocaine in the supernatant 
of hepatocytes decreased obviously from one hour after adding the drug, while it kept unchanged in 
the supernatant of BECs. The BECs were tested in the 7th week after culture. Each point represented 
the mean of six experiments. 
 
 
 
 
                                                                                      *** 
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Figure 3.29  The effect of growth factors and FCS on the proliferation of BECs 
The growth of BECs was measured with MTT method on day 0 and 24 hours after growth factors 
and FCS  was added into basic medium. The value of each factor represented the mean of 6 to 8 
experiments. Control (containing only basic medium), 10ng/ml TGF-ß1 and 1% FCS had no effect 
on BECs growth (* P>0.05). 10ng/ml EGF (** 0.01<P<0.05), 10ng/ml HGF and 10% FCS (*** 
P<0.01) significantly promoted the growth of BECs. The BECs were tested in the 3rd week after 
culture. 
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Figure 3.30  The effect of human serum from hepatectomy patient on the proliferation of 
BECs 
The growth of BECs was measured with MTT method on day 0 and 48 hours after the serum (5%) 
was added into culture medium. The basic medium (control) and the serum taken before operation 
(0) had no effect on the growth of BECs. (* P>0.05), the serum taken after operation (day1-5: 1-5) 
significantly promoted the growth of BECs.(** P<0.01) Each value represented the mean of six 
experiments. The BECs were tested in the 7th week after culture. 
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4. DISCUSSION 
 
4.1. Isolation, culture and characterization of human hepatocytes 
Human hepatocytes were isolated with EGTA and collagenase perfusion method in this study. The 
viability of freshly isolated human hepatocytes from different liver tissues was between 65% and 
85%, and the primary hepatocytes could survive in the collagen G coated culture plate for 2 to 4 
weeks. During this time, the hepatocytes presented the typical polygonal shape, and expressed 
epithelial cells markers, CK 8 and CK 18. They also expressed albumin, ASGPR, alpha1-antitrypsin 
and metabolized lidocaine, which are the characters of differentiated hepatocytes.  
Table 4.1 The markers detected in this experiment and their expressions in different liver cells 
Marker Hepatocytes BECs putative liver stem cells 
ASGPR + - - 
CK 8 + + + 
CK 18 + + + 
CK 7 - + + 
CK 19 - + + 
CK 14 - - + 
c-kit - + (some) + 
Chromogranin-A - - + 
Albumin + - + 
AFP - - + 
Alpha1-antitrypsin + - + 
Vimentin - - + 
Cytochrome P450 + - - 
 
 
4.2. Isolation, culture and characterization of human intrahepatic BECs 
Human intrahepatic BECs were isolated with differential density centrifugation and 
immunomagnetic separation method from different liver tissues. BECs could proliferate in the 
culture medium (containing EGF and HGF) for at least 3 weeks, and some BECs proliferated for 
more than 18 weeks and were passaged for 12 times. Primary BECs were small and oval, and they 
expressed biliary cell markers (CK 7 and CK 19) and epithelial cell markers (CK 8 and CK 18), 
while they did not express desmin (marker of hepatic stellate cell), factor VIII (marker of 
endothelial cell), vimentin, alpha1-antitrypsin. All of these showed their biliary origin. 
However, in this study, our further characterization repeatedly found that proliferating BECs 
not only kept on expressing CK 7, CK 19, CK 8 and CK 18, but some also expressed c-kit, 
chromogranin-A, albumin, AFP, vimentin (after passage), alpha1-antitrypsin, which are the 
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markers of liver stem cells. Some of these BECs had the morphology of hepatocytes and could 
survive for more than 4 weeks without the change of medium. All of these phenomena 
suggested that there were some liver stem-like cells in intrahepatic BECs in vitro. 
 
4.2.1. Expression of c-kit and chromogranin-A by the BECs and its significance 
c-kit is the receptor of stem cell factor (SCF). The stem cell factor and c-kit system is of critical 
importance for early epithelial stem cell differentiation in hematopoiesis or gametogenesis. Recent 
studies suggest that SCF and c-kit may also be involved in early growth and development of liver 
stem cells. Up-regulation of SCF and c-kit has been demonstrated in AAF-treated partially 
hepatectomized (AAF/PH) rats, in which AAF suppressed the replication of hepatocytes and the 
induction of oval cells was observed (Fujio et al. 1994). A similar increase of SCF and c-kit, 
accompanied by oval cell proliferation, has also been reported in bile duct-ligated rats (Omori et al. 
1997). c-kit displays a peak expression in ductal plate cells in human liver until 22 weeks of 
gestation. In adult human liver, c-kit is detected in the Canal of Hering, which is the distal part of 
bile ductule, and possibly harbours liver stem cells (Theise et al. 1999). In severe human liver 
disease, such as fulminant hepatic failure, the expression of c-kit in the liver increased and some c-
kit positive cells were also found integrated into bile ducts (Baumann et al. 1999). It was reported 
that isolated c-kit positive cells in human liver could differentiate into biliary cells in vitro (Crosby 
et al. 2001). In this experiment, some freshly isolated BECs and passsaged BECs were positive for 
the staining of c-kit, and this indicated that they might come from the Canal of Hering and possibly 
be related with an activation of liver stem cells in vitro. 
Chromogranin-A was not detected in normal human liver. However, in liver regeneration after 
submassive necrosis and chronic cholestasis, putative progenitor cells in the vicinity of portal tracts, 
reactive bile ductule and hepatocyte-like cells were positive for the staining of chromogranin-A 
(Roskams et al. 1998). Thus, the expression of chromogranin-A by BECs in vitro could be the result 
of activation of putative liver stem cells. 
 
4.2.2. Expression of AFP by the BECs and its significance 
Using immunohistochemistry method, AFP expression was found in distinct BECs at different 
passages, including the BECs from normal donor liver tissue (No. 4 BECs). The expression of AFP 
mRNA was also identified in the BECs from No. 2 (at 8 weeks after culture), No. 3 (at 5 weeks 
after culture) and No. 4 (at 5 weeks after culture) liver tissues.  
AFP is the major serum glycoprotein and carrier of polyunsaturated fatty acids during embryo-fetal 
development in vertebrates, and AFP synthesis is the characteristic of fetal cells. AFP appears to be 
one of the earliest markers of endodermal commitment toward liver cells, and AFP expression can 
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first be detected at 4 weeks of gestation in human. During the first weeks of biliary development 
from ductal plate cells (at about 7-9 weeks of gestation), the cells are also positive for AFP, which 
eventually becomes lost in developing bile duct cells (Haruna et al. 1996). Normal adult human 
liver do not express AFP. However, in normal rat liver, AFP mRNA was detected in situ 
hybridization in occasional nonparenchymal cells located in portal tracts, and these cells might be 
the progenitors of oval cells induced by some carcinogens (Alpini et al. 1992) (Lemire and Fausto 
1991). Expression of AFP by human intrahepatic BECs in vitro strongly suggested the existence 
and activation of putative liver stem cells. 
Additionally, freshly isolated BECs derived from AIH liver tissue (No. 7 BECs) were also positive 
for AFP. These positive cells could be ductular cells which were detected in chronic liver disease as 
reported and might be the result of activation of putative liver stem cells in vivo. 
 
4.2.3. Expression of albumin and alpha1 antitrypsin by the BECs and its significance 
Using RT-PCR technique, albumin mRNA (567bp) was positive in the BECs in each passage. 
However, with indirect immunofluorescence staining method, primary BECs were negative for the 
staining of albumin, while the passaged BECs (from the 1st to the 11th passage) become positive. 
Alpha1-antitrypsin was positive in the passaged BECs (the 5th passage) with immunohistochemical 
staining. 
It was reported that BECs purified with immunomagnetic separation method were contaminated by 
less than 1% hepatocytes (Joplin et al. 1990), and this could result the false positive of albumin 
mRNA in primary BECs. But in this experiment, albumin mRNA was also positive in the BECs 
from the 1st to the 11th passage. After the BECs were passaged for 11 times and survived in vitro for 
more than 4 months, the existence of contaminated hepatocytes was very unlikely. Moreover, the 
double-fluorescent immunostaining disclosed the co-expression of CK 7 and albumin, and this 
further supported that albumin positive cells were of biliary origin. 
In human, albumin is expressed by both fetal and mature hepatocytes, and it is also expressed by 
ductal plate cells of fetal liver and ductular hepatocytes in diseased human liver. Bile duct cells and 
bile ductules are negative for albumin. Alpha1-antitrypsin has the similar expression pattern to 
albumin. Albumin mRNA was also detected in occasional nonparenchymal cells located in portal 
tracts in normal rat liver (Alpini et al. 1992). Thus, the expression of albumin and alpha1-antitrypsin 
by human intrahepatic BECs also indicated that there might be co-purified putative liver stem cells 
and they were activated in vitro. 
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4.2.4. Expression of vimentin by the BECs and its significance 
Vimentin is considered as the marker of mesenchymal cells. However, in human developing liver, 
vimentin is detected in ductal plate and bile duct cells in the period between 9 and 36 weeks of 
gestation (Haruna et al. 1996). In normal human adult liver, only rare bile duct cells are positive for 
vimentin. Increased expression is associated with acute biliary obstruction and chronic liver 
disorders in human and oval cell proliferation in rat. 
In this experiment, vimentin was negative in primary BECs, but positive in passaged BECs. 
Double-fluorescent immunostaining found the vimentin positive cells co-expressed CK 18 or CK 7, 
and this excluded the contamination by fibroblasts (mesenchymal cells). The expression of vimentin 
by proliferating human intrahepatic BECs again implied the activation of putative liver stem cells in 
vitro. 
 
4.2.5. Lidocaine metabolism 
Although some BECs in this experiment expressed albumin and alpha1-antitrypsin which are also 
the markers of hepatocytes, they could not metabolize lidocaine as hepatocytes. Lidocaine is 
metabolized by cytochrome P450 monooxygenase that exists only in hepatocytes. This result 
further excluded a major contamination with hepatocytes and indicated that albumin or alpha1-
antitrypsin positive cells could be immature liver progenitor cells. 
 
The expression pattern of these BECs are similar to the bipotential liver progenitor cells in 
the human developing liver or oval-like cells in ductular reaction in some human diseased 
livers. This raised the next questions: What was the origin of the proliferating intrahepatic 
BECs in vitro? Did intrahepatic biliary tree consist of liver stem cells? How was liver stem cell 
activated in vitro? 
 
4.3. Origin of isolated HEA-positive human intrahepatic BECs 
In this study, human intrahepatic BECs were purified with immunomagnetic (anti-HEA) separation 
method. HEA is a 34 KD surface glycoprotein expressed by many kinds of epithelial cells. 
However, in human liver, HEA was expressed only by biliary epithelium. Using 
immunohistochemistry technique, it was reported that large and medium sized bile duct, as well as 
bile ductule epithelium was stained positively for HEA antibody, but the hepatic cords themselves 
were completely negative (Joplin et al. 1989). Primary BECs isolated with immunomagnetic 
separation (anti-HEA) method were strong positive with staining of HEA in this experiment, and 
this identified their biliary origin.  
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The bile ductule is the smallest branch of the bile duct system. The Canal of Hering is the terminal 
portion of the bile ductule and it connects with the bile canaliculus which is formed by hepatocytes. 
The canal of Hering is composed on one side by the last hepatocyte and on the other side by the first 
biliary epithelial cell. It has been suggested that the Canal of Hering consists of, or harbours 
facultative hepatic stem cells in human. In normal human liver, the cells in the Canal of Hering 
express CK 19, c-kit, while do not stain for HepPar 1 and AFP (Theise et al. 1999). In this study, it 
was found that some BECs were positive with the staining of c-kit, and it indicated that these cells 
possibly came from the Canal of Hering.  
Further, we found that some proliferating intrahepatic BECs also expressed albumin, AFP, alpha-1 
antitrypsin and chromogranin-A which are the characters of liver stem cells. With double-
fluorescent immunostaining, the cells, which co-expressed CK 7 and albumin, CK 8 and albumin, 
CK 7 and vimentin, CK 18 and vimentin were identified. These cells may derive from liver stem 
cells that existed in the intrahepatic BECs. In other words, some of the intrahepatic BECs may have 
the potential of liver stem cells. However, some CK 7-expressing BECs did not express albumin, 
and this showed that they were mature biliary cells which possibly came direct from medium and 
large branches of bile duct, or from the biliary differentiation of liver stem cells. 
Compared with mature cells, stem cells have a greater potential to survive and proliferate. In this 
experiment, it was found that the yield of intrahepatic BECs isolated from end-staged diseased PBC 
and AIH liver tissues was very high, and the primary cells were confluent in about 5 to 7 days after 
culture. In these diseased liver tissues there were proliferation of bile ducts. While for the primary 
BECs isolated from children liver tissues, they were confluent in about 11 days after culture. 
However, BECs derived from PBC or AIH had a short proliferation period (4 weeks on the 
average). Although the yield of the BECs isolated from children liver tissues was much lower that 
that from PBC or AIH liver tissues, they had a longer proliferating time (7 to 12 weeks). This might 
imply that mature BECs took most part in the BECs isolated from PBC and AIH liver tissues, while 
BECs derived from child liver tissue might contain more cells with liver stem cell potential. 
Thus, the isolated intrahepatic BECs may contain biliary cells in various differentiating stages. Bile 
ductule may contain liver stem cells and their early differentiating progeny, and these cells have a 
great potential to proliferate in vitro. 
There are two convincing evidences suggesting that intrahepatic biliary tree in rodent liver may 
contain liver stem cell. Oval cells in rodent liver are believed to be progeny of liver stem cells, and 
they arise in the periportal area and form ductlike structure. The first evidence is that with the 
cholangiogram, the continuity between this ductlike structure and the existing portal bile ducts have 
been found (Dunsford et al.  1985) (Lenzi et al. 1992). The second is that bile ductular damage by 
toxin (4,4‘-diaminodiphenylmethane, DAPM) inhibits oval cell activation (Petersen et al. 1997). 
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4.4. Possible mechanism of activation of liver stem cells in vitro: role of growth factors 
In this experiment, it was found that freshly isolated BECs or BECs in primary culture did not 
express albumin (at protein level by indirect immunofluorescent staining) and vimentin, while some 
cells acquired the expression of these two proteins and other liver stem cells markers during long 
term cell culture. Therefore, BECs with liver stem cell potential might be activated in vitro, and this 
might be related with the growth factors (EGF, HGF) in culture medium.  
TGF-α and HGF are two important growth-promoting factors in normal liver regeneration. TGF-α 
is an autocrine growth factor, which is produced by hepatocytes and acts on it through binding the 
EGF receptor. HGF is produced by non-parenchymal cells (hepatic stellate cells) and stimulates 
hepatocyte replication by a paracrine or endocrine mechanism. HGF is the most potent known 
mitogen for hepatocytes in vitro. In the model of oval cell activation (AAF/PH), the first cells 
entering DNA synthesis are OV-6 and desmin positive cells in the periportal area and in the Glisson 
capsule. Coincident with the appearance of these cells, an increase in the expression of TGF-α and 
HGF was observed (Evarts et al. 1993). And this suggested that TGF-α and HGF were closely 
associated with the early activation of the liver stem cell compartment. EGF has the similar function 
to TGF-α, and they share the same receptor. In vivo infusion of EGF and HGF enhanced the 
mitogenic response of rat oval cells while decreased their apoptosis (Nagy et al. 1996). This further 
indicated that EGF and HGF were also essential to maintain the survival of oval cells. In human, 
oval-like cells were found in fulminant hepatic failure patient who had very high concentration of 
HGF both in peripheral blood and in liver tissue, and there might be relation between HGF and 
activation of liver stem cell. 
In this experimental part, it was demonstrated that EGF (10ng/ml) or HGF (10ng/ml) significantly 
promoted the growth of BECs, and TGF-ß1 (10ng/ml) had no effect on their growth. The serum 
from the post-hepatectomy patient also stimulated the proliferation of BECs, while serum from the 
same patient taken before operation had no such effect. This can be explained by the increase of 
growth factors (TGF-α and HGF) concentration during liver regeneration. TGF-ß1 has 
antiproliferative effect on hepatocytes and stimulate hepatic stellate cells to produce extracellular 
matrix protein. TGF-ß1 is produced by hepatic stellate cells and acts in an autocrine/paracrine 
fashion (Fausto, 2000). As BECs did not grow in the basic medium in this experiment, the anti-
proliferative effect of TGF-ß1 could not be found.  
In this study, EGF and HGF not only could promote the proliferation of BECs in vitro, but might 
also activate the co-purified liver stem cells as they do in vivo. 
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4.5. Conclusion and prospective 
From both normal and diseased human liver tissue, intrahepatic BECs were successfully isolated 
and cultured for some time in vitro. The characterization of these BECs demonstrated their specific 
phenotypes, moreover, liver stem-like cells were found in these BECs in vitro. This result supported 
the hypothesis that human biliary tree might also contain liver stem cells. 
The discovery of liver stem cell in adult liver can be also used to understand the mechanism of 
hepatocarcinogenesis and cholangiocarcinogenesis. Dedifferentiation of mature cell and maturation 
arrest of liver stem cell are two models to explain the cell origin of primary liver (Sell1993) (Sell 
and Dunsford 1989). The discovery of liver stem cell in adult liver favours the maturation arrest 
theory. The liver stem cell may arrest in different differentiating stage, and transform into 
hepatoblastoma, hepatocellular carcinoma and cholangiocarcinoma. The further characterization of 
these primary liver tumors with liver stem cell markers may help to find their origin. 
The liver stem cells have a great potential to proliferate. If they could be induced to differentiate 
into mature hepatocytes, there would be wide usage for hepatocyte transplantation and gene therapy 
of liver diseases. 
However, based on this study, it is not clear how many putative liver stem cells were co-purified 
with the BECs, and how they were activated in vitro. Although the later is considered to be the 
action of growth factors (EGF and HGF), the exact dosage, duration and combination for the 
growth factors to activate liver stem cell need further investigation.  
Based on this experiment, the location of putative liver stem cell in biliary tree also could not be 
identified. Some BECs were positive for the staining of c-kit, and this indicated they might come 
from the Canal of Hering. But the expression of c-kit might also be the result of activation of liver 
stem cell in vitro. 
The putative liver stem cell in adult liver has been thought to be the remnant from developing liver 
in embryo. However, in past three years, there have been growing reports that bone marrow cells 
are capable of differentiate into hepatocytes in mice, rat and human (Theise et al. 2000b) (Alison et 
al. 2000; Lagasse et al. 2000; Theise et al. 2000a). This means that bone marrow cells may also be 
liver stem cells. Further studies to explore the proliferation and differentiation mechanism of liver 
stem cells hopefully will provide new insights, ultimately leading to better treatment of end-staged 
liver diseases. 
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5. ABBREVIATIONS 
 
 
 
AAF 2-acetylaminofluorence 
AAT alpha1-antitrypsin 
AFP alpha-fetoprotein 
ASGPR asialoglycoprotein receptor 
γ-GT gamma glutamyl transferase 
BECs biliary epithelial cells 
CK cytokeratin 
DAPM 4,4‘-diaminodiphenylmethane 
DHs ductular hepatocytes 
DMEM dulbecco’s modified eagle medium 
DMSO dimethylsulfoxid 
FACS fluorescence activating cell sorting 
FNH focal nodular hyperplasia 
HBSS hanks’ balanced salt solution 
HEA human epithelial antigen 
HepPar1 hepatocyte parrafin 1 
HGF hepatocyte growth factor 
HSC hepatic stellate cells 
NPCs nonparenchymal cells 
RT-PCR reverse transcription polymerase chain reaction 
SCF stem cell factor 
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6. SUMMARY 
 
Human hepatocytes were isolated with EGTA and collagenase perfusion method from eleven 
different liver tissues in this experiment. The viability of freshly isolated human hepatocytes was 
between 65% and 85%, and the primary hepatocytes could survive in the collagen G coated culture 
plate for 2 to 4 weeks. During this time, the hepatocytes presented the typical polygonal shape, and 
expressed epithelial cell markers, CK 8 and CK 18. They also expressed albumin, ASGPR, alpha1-
antitrypsin and metabolized lidocaine, which are the characters of differentiated hepatocytes. 
Human intrahepatic BECs were isolated with immunomagnetic separation method from ten 
different liver tissues. The BECs could proliferate in the culture medium (containing EGF and 
HGF) for at least 4 weeks, and some BECs had proliferated for more than 18 weeks and been 
passaged for 12 times. Primary BECs were small and oval, and they expressed biliary cell markers 
(CK 7 and CK 19) and epithelial cell markers (CK 8 and CK 18), while they did not express desmin 
(marker of hepatic stellate cell), factor VIII (marker of endothelial cell). 
The further characterization repeatedly found that proliferating BECs not only kept on expressing 
CK 7, CK 19, CK 8 and CK 18, but some also expressed c-kit, chromogranin-A, albumin, AFP, 
vimentin (after passage), alpha1-antitrypsin, which are the markers of liver stem cells. Some BECs 
had the morphology of hepatocytes and could survive for more than 4 weeks without the change of 
culture medium. Double-fluorescent immunostaining identified the biliary origin of these cells. All 
of these phenomena suggested that there were some liver stem-like cells co-purified with 
intrahepatic BECs in vitro. Liver stem cells might be residents among intrahepatic BECs and 
activated in vitro by the growth factors. 
This finding supported the hypothesis that the human biliary tree may harbour liver stem cells, and 
the liver stem cells could be co-purified with intrahepatic BECs. 
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